Life Cycle Investment Partners Ltd purchased a new stake in PACCAR Inc. (NASDAQ:PCAR – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 326,745 shares of the company’s stock, valued at approximately $35,782,000. Life Cycle Investment Partners Ltd owned 0.06% of PACCAR at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in PCAR. Ares Financial Consulting LLC bought a new stake in PACCAR in the 4th quarter valued at $27,000. Elyxium Wealth LLC bought a new stake in PACCAR in the 4th quarter valued at $30,000. Wealth Watch Advisors INC bought a new stake in PACCAR in the 3rd quarter valued at $32,000. Camelot Portfolios LLC bought a new stake in PACCAR in the 4th quarter valued at $33,000. Finally, AlphaQuest LLC bought a new stake in PACCAR in the 3rd quarter valued at $38,000. Institutional investors own 64.90% of the company’s stock.
PACCAR Stock Performance
NASDAQ:PCAR opened at $109.35 on Friday. The stock’s 50-day simple moving average is $117.77 and its 200 day simple moving average is $115.75. The firm has a market capitalization of $57.55 billion, a PE ratio of 23.27, a price-to-earnings-growth ratio of 1.02 and a beta of 1.02. The company has a quick ratio of 2.91, a current ratio of 3.11 and a debt-to-equity ratio of 0.52. PACCAR Inc. has a twelve month low of $90.05 and a twelve month high of $131.88.
PACCAR Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Wednesday, May 13th will be paid a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This is a positive change from PACCAR’s previous quarterly dividend of $0.33. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.3%. PACCAR’s payout ratio is 29.79%.
Analysts Set New Price Targets
PCAR has been the topic of several recent research reports. Wells Fargo & Company set a $125.00 price objective on PACCAR and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Morgan Stanley set a $109.00 price target on PACCAR and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. decreased their price target on PACCAR from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Citigroup restated a “neutral” rating and issued a $125.00 price target (down from $130.00) on shares of PACCAR in a research report on Thursday, April 30th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of PACCAR in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $122.00.
Read Our Latest Analysis on PACCAR
PACCAR Company Profile
PACCAR Inc is a global technology leader in the design, manufacture and customer support of light-, medium- and heavy-duty commercial vehicles. The company’s products are marketed under well-known brand names including Kenworth, Peterbilt and DAF and span vocational and long-haul applications. PACCAR’s core business includes vehicle engineering and assembly as well as the supply of components and proprietary powertrain systems designed to meet regulatory and customer performance requirements.
In addition to truck manufacturing, PACCAR operates a comprehensive aftermarket parts business, distributes used trucks and provides commercial vehicle financing and leasing through its financial services operations.
Featured Articles
- Five stocks we like better than PACCAR
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for PACCAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PACCAR and related companies with MarketBeat.com's FREE daily email newsletter.
